Company Description
QTREX Quantum Ltd., engages in the research, development, manufacturing, and marketing of proprietary life support technologies for the treatment of acute respiratory failure and advanced connectivity solutions for the quantum computing industry in Israel and USA.
It offers INSPIRA ART100, a life support system used in procedures requiring cardiopulmonary bypass for six hours or less.
It also offers HYLA blood sensor, which is designed to perform real-time sampling and analysis of key blood parameter measurements.
In addition, The company offers cryogenic interconnects systems are generally built from multiple discrete components assembled and verified in a manual process.
It also develops a monolithic interconnect architecture that integrates the conductor, radio-frequency dielectric, shielding, thermal management, and mechanical routing into a single engineered structure, designed to replace discrete, manually assembled cabling and support higher channel density and reliability.
In addition, It offers AME Platform, provides the manufacturing foundation for our quantum connectivity development efforts and also operates as a commercial business serving customers across aerospace, missile, defense, and advanced electronics sectors.
The company was formerly known as Inspira Technologies Oxy B.H.N. Ltd. and changed its name to QTREX Quantum Ltd. in May 2026.
QTREX Quantum Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.
| Country | Israel |
| Founded | 2018 |
| IPO Date | Jul 14, 2021 |
| Industry | Computer Hardware |
| Sector | Technology |
| Employees | 37 |
| CEO | Dagi Ben-Noon |
Contact Details
Address: 2 Ha-Tidhar St. Ra'anana, 4366504 Israel | |
| Phone | 972 4 623 0333 |
| Website | q-trex.com |
Stock Details
| Ticker Symbol | QTEX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1837493 |
| ISIN Number | IL0011715781 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dagi Shahar Ben-Noon | Co-Founder, Chief Executive Officer and Director |
| Yafit Tehila | Chief Financial Officer |
| Avi Shabtai | Chief Operating Officer and Vice President of Research and Development |
| Daniella Yeheskely-Hayon M.B.A., Ph.D. | Chief Technology Officer |
| Sivan Ozeri | Administrative Manager |
| Adi Shmueli | Director of Marketing |
| Mike Hershkovitz | Vice President of Global Sales |
| Yoav Rozanovich | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 21, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Jul 21, 2026 | 6-K | Report of foreign issuer |
| Jul 21, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 17, 2026 | 6-K | Report of foreign issuer |
| Jul 15, 2026 | 25-NSE | Filing |
| Jul 14, 2026 | 6-K | Report of foreign issuer |
| Jul 13, 2026 | EFFECT | Notice of Effectiveness |
| Jul 13, 2026 | SCHEDULE 13G/A | Filing |
| Jul 7, 2026 | POS AM | Post-Effective amendments for registration statement |
| Jul 1, 2026 | 6-K | Report of foreign issuer |